Lundbeck Rebuilds Neurology Pipeline with Abide Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)
Published: 9 May-2019
DOI: 10.3833/pdr.v2019.i5.2421 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Lundbeck has moved to expand its reach in the neurology market with the acquisition of Abide Therapeutics, a company focused on targeting enzymes of the serine hydrolase class, for a deal value of up to US$400 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS